" class="no-js "lang="en-US"> Naresh Vempala - Medtech Alert
Wednesday, July 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Naresh Vempala

Naresh Vempala

About Naresh Vempala

Dr. Vempala has a Ph.D. in cognitive science minoring in AI, an M.S. in computer science from the Center for Advanced Computer Studies, University of Louisiana at Lafayette, and an M.S. in civil engineering from Mississippi State University. He has over 20 years of experience in industry and academia.

Related Story

Artificial Intelligence

 Researchers Announce AI Models That Can Predict Blood Biomarker Risk | Pharmtech Focus

NuraLogix Researchers Announce AI Models That Can Predict Blood Biomarker Risk

September 1 2022

Researchers at NuraLogix, a global leader in HealthTech AI, announced today that they have developed […]